Text
L-ornithine can be an additional therapy to boost the efficacy of ustekinumab in people with Crohn’s disease.
By addressing biases and increasing diversity in microbiota studies, researchers can develop more accurate and inclusive health strategies for women of different backgrounds.
This pioneering three-in-one formula uniquely combines pasteurized Akkermansia muciniphila AKK PROBIO, DigeSEB® broad-spectrum digestive enzymes, and B-Complex vitamins.
Reproducible biomarkers produced by several bacteria show potential as a non-invasive tool for IBD diagnosis, discriminating ulcerative colitis and Crohn’s disease patients from healthy individuals.
Treatment with the probiotic Lactobacillus murinus improved social behavior and partially restored gut and brain function.
Industry
Sponsored by
Cerenity™ improves mobility, strength, and muscle function in older adults by modulating the gut-muscle axis.
The Human Gut Microbiome Reference Material (RM) promises to standardize and enhance research efforts in a field poised to transform healthcare.
Inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are long-term conditions involving gut inflammation caused by an excessive immune response. Now, a study done in mice found…
The findings of a recent study suggest a potential role of gut microbiota and microbial metabolites in the link between sugar-sweetened beverages intake and diabetes risk.
MaaT013, a Microbiome Ecosystem Therapy™ (MET), is designed to restore the gut microbiome in pediatric patients aged 6 to 18 years with steroid-resistant aGvHD.
